| Original language | English (US) |
|---|---|
| Pages (from-to) | 280-281 |
| Number of pages | 2 |
| Journal | JAMA Oncology |
| Volume | 9 |
| Issue number | 2 |
| DOIs |
|
| State | Published - Feb 16 2023 |
ASJC Scopus subject areas
- Oncology
- Cancer Research
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Tissue-Based PD-L1 Expression Is the Strongest Predictor of Overall Survival Benefit from ICI in Advanced Gastroesophageal Cancer - Reply. / Yoon, Harry H.; Shi, Qian; Ajani, Jaffer A.
In: JAMA Oncology, Vol. 9, No. 2, 16.02.2023, p. 280-281.Research output: Contribution to journal › Comment/debate › peer-review
}
TY - JOUR
T1 - Tissue-Based PD-L1 Expression Is the Strongest Predictor of Overall Survival Benefit from ICI in Advanced Gastroesophageal Cancer - Reply
AU - Yoon, Harry H.
AU - Shi, Qian
AU - Ajani, Jaffer A.
N1 - Funding Information: Conflict of Interest Disclosures: Dr Ajani reported honoraria from Acrotech Biopharma, Aduro Biotech, Amgen, Astellas Pharma, AstraZeneca, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, DAVA Pharmaceuticals, Fresenius Kabi, Gilead Sciences, GRAIL, Lilly, Merck, Novartis, OncoTherics, Servier; Zymeworks, Surface Oncology, and Arcus; consulting/advisory fees from American Cancer Society, BeiGene, Bristol Myers Squibb, Insys Therapeutics, Merck, and Vaccinogen; and grants from Amgen, Astellas Pharma, Bristol Myers Squibb, Daiichi Sankyo, Delta-Fly Pharma, Gilead Sciences, Lilly/ImClone, Merck, Novartis, ProLynx, Roche/Genentech, Taiho Pharmaceutical, Takeda, Zymeworks, and LaNova, all outside the submitted work. Dr Yoon reported serving on advisory boards for ALX Oncology, Amgen, Astellas, AstraZeneca, BeiGene, Bristol Myers Squibb (BMS), OncXerna, MacroGenics, Merck, Novartis, and Zymeworks and receiving grants from Boston Biomedical, Lilly/ImClone, Merck, and Roche/Genentech outside the submitted work. Dr Shi reported receiving personal fees from Yiviva Inc (DSMB), Boehringer Ingelheim Pharmaceuticals, Inc (consulting/advisory role), Regeneron Pharmaceuticals, Inc (consulting/advisory role), Hoosier Cancer Research Network (DSMB), and Kronos Bio (consulting/advisory role) and grants (research funding to institution) from BMS/Celgene, BMS, Roche/Genentech, Janssen, and Novartis outside the submitted work.
PY - 2023/2/16
Y1 - 2023/2/16
UR - http://www.scopus.com/inward/record.url?scp=85148306778&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85148306778&partnerID=8YFLogxK
U2 - 10.1001/jamaoncol.2022.6708
DO - 10.1001/jamaoncol.2022.6708
M3 - Comment/debate
C2 - 36547945
AN - SCOPUS:85148306778
SN - 2374-2437
VL - 9
SP - 280
EP - 281
JO - JAMA oncology
JF - JAMA oncology
IS - 2
ER -